Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?

Oncologist

Volumn 17, Issue 10, 2012, Pages 1223-1224

  Sondak, Vernon K ^a,b   Kudchadkar, Ragini ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; B RAF KINASE; INTERFERON; IPILIMUMAB; PEGINTERFERON; PEGINTERFERON ALPHA2B; PLACEBO;

ADJUVANT THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); DISTANT METASTASIS FREE SURVIVAL; DRUG MEGADOSE; FOOD AND DRUG ADMINISTRATION; HUMAN; MELANOMA; METASTATIC MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL;

FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SKIN NEOPLASMS;

EID: 84868088932     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0368     Document Type: Article

References (8)

1. Eggermont AM, Suciu S, MacKie R et al. Postsurgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial. Lancet 2005;366:1189-1196.
2. Herndon TM, Demko SG, Jiang X et al. U.S. Food and Drug Administration approval: Peginterferonalfa-2b for the adjuvant treatment of patients with melanoma. The Oncologist 2012;17:1323-1328.
3. Daud AI, Xu C, Hwu WJ et al. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol 2011;67:657-666.
4. Eggermont AM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117-126.
5. Hauschild A, Weichenthal M, Rass K et al. Efficacy of low-dose interferon α2a 18 versus 60 months of treatment in patients with primary melanoma of 1.5mmtumor thickness: Results of a randomized phase III DeCOG trial. J Clin Oncol 2010;28:841-846.
6. Eggermont AM, Bouwhuis MG, KruitWHet al. Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991). Cancer Chemother Pharmacol 2010;65:671-677.
7. Eggermont AMM, Suciu S, Testori A et al. Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48:218-225.
8. Eggermont AMM, Testori A, Maio M et al. Anti-CTLA-4 antibody adjuvant therapy in melanoma. Semin Oncol 2010;37:455-459.